Fact-checked by Grok 2 weeks ago

Receptor modulator

A receptor modulator is a molecule, either endogenous or exogenous, that binds to a specific receptor—a protein or protein complex that recognizes chemical signals—and thereby regulates its function, influencing cellular responses in biological systems.^[1] These modulators are fundamental to pharmacology, as they form the basis for drug actions by mimicking, enhancing, or blocking natural signaling pathways.^[1] Receptor modulators can be categorized based on their effects on receptor activity. Agonists bind to the receptor's orthosteric site (the primary ligand-binding location) and activate it, eliciting a biological response proportional to their efficacy; full agonists produce the maximum response, while partial agonists generate a submaximal effect even at full occupancy.^[1] Antagonists, in contrast, bind without activating the receptor, thereby preventing agonists from binding and blocking the response; they are often competitive, shifting dose-response curves rightward without altering maximum efficacy.^[1] Inverse agonists reduce the receptor's constitutive (baseline) activity, which is particularly relevant for receptors with inherent signaling in the absence of ligands, such as certain G protein-coupled receptors (GPCRs).^[1] Beyond orthosteric interactions, allosteric modulators bind to distinct sites on the receptor, altering its conformation to enhance (positive allosteric modulators, PAMs) or diminish (negative allosteric modulators, NAMs) the binding affinity or efficacy of orthosteric ligands without directly activating the receptor themselves.^[2] This mechanism allows for finer, subtype- or tissue-specific regulation, expanding therapeutic potential by avoiding broad activation or blockade.^[2] For instance, allosteric modulation is key in targeting GPCRs, which are targeted by about 36% of approved drugs.^[3] Selective receptor modulators represent a specialized class that exhibit agonist, antagonist, or partial agonist effects in a tissue- or cell-specific manner, due to differences in receptor conformation, co-regulator recruitment, or local cellular environment.^[4] Prominent examples include selective estrogen receptor modulators (SERMs) like tamoxifen, which acts as an antagonist in breast tissue to treat hormone-sensitive cancers but as an agonist in bone to prevent osteoporosis.^[5] Similarly, selective androgen receptor modulators (SARMs) such as enobosarm promote anabolic effects in muscle while minimizing androgenic side effects in prostate tissue.^[4] The study and development of receptor modulators have revolutionized medicine, enabling targeted therapies for conditions ranging from cardiovascular diseases and neurological disorders to cancers and autoimmune diseases.^[1] Advances in structural biology, such as X-ray crystallography and molecular dynamics simulations, continue to refine our understanding of modulator-receptor interactions, facilitating the design of more precise drugs with reduced off-target effects.^[6]

Overview

Definition

A receptor modulator is a molecule, either endogenous or exogenous, that binds to a specific receptor protein and thereby alters its function, potentially by activating, inhibiting, or otherwise modulating associated signaling pathways to influence cellular responses.^[7] These modulators, often referred to as ligands in pharmacological contexts, interact with receptors located on the cell surface or within the cell, initiating conformational changes that propagate signals leading to physiological effects such as gene expression regulation or ion flux alterations.^[8] Receptor modulators primarily target major classes of receptors, including G protein-coupled receptors (GPCRs), which are seven-transmembrane proteins that couple to heterotrimeric G proteins to activate intracellular pathways like cyclic AMP production or calcium mobilization upon ligand binding; ion channel receptors, such as ligand-gated channels that open or close in response to modulators to permit ion flow across the membrane; and nuclear receptors, intracellular transcription factors that, when bound by lipophilic modulators like steroid hormones, translocate to the nucleus to regulate gene transcription.^[8] Through these interactions, modulators fine-tune cellular responses in diverse systems, from neurotransmission in the nervous system to metabolic regulation in endocrine tissues.^[8] A key distinction in receptor pharmacology is between affinity, which measures the strength of binding between the modulator and receptor (quantified by the dissociation constant Kd, where lower values indicate tighter binding), and efficacy, which refers to the modulator's capacity to activate the receptor and produce a maximal biological response once bound (with full agonists exhibiting high efficacy and antagonists showing none).^[9] This separation allows modulators with similar affinity to elicit varying degrees of response, underpinning selective therapeutic targeting.^[9] The concept of receptors as sites modulated by ligands originated in the early 20th century, with physiologist J.N. Langley coining the term "receptive substance" in 1905 to describe entities on cells that bind drugs like nicotine to elicit responses, laying the foundation for modern receptor theory.^[1] By the mid-20th century, this evolved with the development of drugs such as beta-blockers, which exemplify receptor modulators by competitively inhibiting adrenergic receptors to reduce sympathetic signaling in cardiovascular applications.^[10]

Pharmacological Role

Receptor modulators play a central role in pharmacology by enabling targeted interventions in disease states through precise regulation of cellular signaling pathways. These agents are widely used to treat various conditions by either enhancing or inhibiting receptor activity to restore physiological balance. For instance, opioid receptor modulators, such as mu-opioid agonists like morphine, are essential for managing severe pain by activating receptors in the central nervous system to suppress nociceptive signaling.^[11] Similarly, adrenergic receptor modulators, including beta-blockers like propranolol that act as antagonists at beta-1 and beta-2 receptors, are cornerstone therapies for hypertension, reducing cardiac output and vascular resistance to lower blood pressure.^[12] Antihistamines, functioning as H1 receptor antagonists (e.g., diphenhydramine), alleviate allergic reactions by blocking histamine-mediated responses in tissues, thereby mitigating symptoms like itching and swelling.^[13] In drug development, receptor modulators are identified and optimized using high-throughput screening (HTS) techniques, which allow researchers to test vast libraries of compounds against specific receptor targets to discover leads that produce desired therapeutic effects while minimizing adverse reactions. This approach facilitates the design of drugs with improved efficacy and safety profiles, such as selective modulators that avoid broad-spectrum activation of related receptors. For example, analogous to receptor modulation, enzyme modulators like statins inhibit HMG-CoA reductase to lower cholesterol levels and prevent cardiovascular events, highlighting the broader paradigm of targeted inhibition in pharmacotherapy.^[14]^[15] Despite their utility, challenges in developing receptor modulators include off-target effects, where unintended interactions with non-target receptors can lead to toxicity or reduced efficacy, necessitating rigorous selectivity profiling during preclinical stages. Achieving high selectivity is critical to mitigate risks like cardiovascular complications or neurological side effects, often requiring advanced computational modeling and iterative structure-activity relationship studies. Receptor modulators constitute a major class of therapeutics, primarily among small-molecule drugs, with G-protein coupled receptor (GPCR)-targeting drugs accounting for approximately 35% of all FDA-approved drugs as of 2018 (a figure that has remained stable in recent years), ion channel targets for 15-18%, and nuclear receptors for approximately 13%, making receptor-based drugs over 50% of approvals.^[16]^[17]

Classification by Intrinsic Activity

Full Agonists

Full agonists are ligands that bind to a receptor and elicit the maximum possible biological response, equivalent to that produced by the endogenous ligand at full receptor occupancy.^[18] They achieve this by possessing both high affinity for the receptor and maximal intrinsic efficacy, fully stabilizing the active conformation of the receptor.^[18] In their mechanism of action, full agonists typically bind to the orthosteric site—the primary ligand-binding pocket on the receptor—and induce a conformational change that shifts the equilibrium toward the active receptor state (R*).^[19] This activation promotes complete signal transduction through downstream pathways, such as G-protein coupling, leading to maximal cellular responses like ion channel modulation or enzyme activation.^[20] For instance, epinephrine serves as a full agonist at beta-adrenergic receptors, where it binds the orthosteric site to activate adenylyl cyclase via Gs proteins, increasing cyclic AMP levels and resulting in bronchodilation and enhanced cardiac contractility.^[21] Similarly, morphine acts as a full agonist at mu-opioid receptors, binding the orthosteric site to activate Gi/o proteins, which inhibit adenylate cyclase, hyperpolarize neurons via potassium channels, and suppress neurotransmitter release for potent analgesia.^[20] The dose-response curve for a full agonist features a characteristic plateau at high concentrations, representing 100% efficacy where further increases in dose yield no additional response.^[22] This contrasts with partial agonists, which exhibit reduced efficacy and fail to reach this maximum even at saturating concentrations.^[18] In clinical applications, full agonists like albuterol, a selective beta-2 adrenergic agonist, are used for emergency treatment of asthma exacerbations; it binds the orthosteric site to relax bronchial smooth muscle via cAMP elevation, providing rapid bronchodilation within minutes.^[23]

Partial Agonists

A partial agonist is a ligand that binds to a receptor and activates it, but elicits a submaximal response compared to a full agonist, even when occupying all available receptors; this reflects an intrinsic efficacy of less than 100%, as the ligand stabilizes a partially active receptor conformation rather than the fully active state.^[24]^[25] The mechanism of partial agonism involves inducing a limited conformational change in the receptor, which partially shifts it toward the active state but does not fully propagate signaling cascades like G-protein coupling or ion channel opening to their maximum extent.^[26] In systems with constitutive receptor activity, partial agonists can reduce basal signaling more than neutral ligands but less than inverse agonists. When co-administered with full agonists, partial agonists can competitively inhibit the stronger response by occupying binding sites, thereby exhibiting antagonist-like effects in environments of high full-agonist activity.^[27] This agonist-antagonist duality arises from their intermediate efficacy, allowing them to modulate receptor signaling in a context-dependent manner relative to the full agonist benchmark of maximal response.^[28] In dose-response curves, partial agonists produce a sigmoidal curve that plateaus at a lower maximum effect (E_max) than full agonists, providing a therapeutic ceiling that limits excessive activation and associated risks like toxicity or dependence.^[29] This property confers advantages in stabilizing dysregulated systems, such as in addiction treatment or psychiatric disorders, by preventing over-stimulation while still providing beneficial agonism. For instance, buprenorphine acts as a partial agonist at mu-opioid receptors with high binding affinity but low intrinsic activity, resulting in reduced euphoria and respiratory depression compared to full agonists like morphine, which lowers the risk of abuse and overdose in opioid use disorder management.^[30] Similarly, aripiprazole functions as a partial agonist at dopamine D2 receptors, stabilizing mesolimbic and mesocortical dopaminergic pathways to alleviate positive and negative symptoms of schizophrenia without fully mimicking dopamine's effects, thus minimizing extrapyramidal side effects.^[31]

Neutral Antagonists

Neutral antagonists are pharmacological agents that bind to a receptor and prevent the binding or activation by agonists, exhibiting no intrinsic efficacy of their own, meaning they neither activate the receptor nor inhibit its basal signaling activity.^[32] This distinguishes them from other modulators by their pure blocking action limited to ligand-dependent responses.^[18] The primary mechanism of neutral antagonists involves competitive inhibition at the orthosteric binding site of the receptor, where they compete directly with agonists for occupancy. This interaction results in a rightward parallel shift of the agonist's dose-response curve, increasing the concentration required for agonist effect without altering the maximum response achievable.^[33] Such behavior is characteristic of reversible competitive binding, as detailed in analyses of receptor interactions.^[34] Representative examples include propranolol, which acts as a neutral antagonist at beta-adrenergic receptors by blocking the effects of epinephrine without intrinsic activity.^[35] Similarly, naloxone functions as a neutral antagonist at mu-opioid receptors, effectively reversing opioid-induced effects such as respiratory depression in overdose scenarios.^[34] The potency of neutral antagonists is often quantified using Schild analysis, where the pA2 value—defined as the negative logarithm of the antagonist concentration that produces a twofold shift in the agonist dose-response curve (log(dose ratio - 1) = pA2)—provides a measure of affinity independent of agonist concentration.^[36] In pharmacological research, neutral antagonists serve as essential tools for dissecting receptor function, allowing isolation of agonist-mediated effects to elucidate signaling pathways without confounding basal activity.^[37]

Inverse Agonists

Inverse agonists are ligands that bind to receptors exhibiting constitutive activity and stabilize the inactive conformation of the receptor, thereby reducing or eliminating the basal level of signaling that occurs in the absence of an agonist.^[38] This effect is particularly relevant in systems where receptors spontaneously adopt an active state, leading to ongoing signaling without ligand stimulation. Constitutive receptor activity serves as a prerequisite for observing inverse agonism, as it establishes a measurable basal tone that can be suppressed.^[18] The mechanism of inverse agonists involves preferential binding to the inactive state of the receptor, shifting the equilibrium away from the active conformation and decreasing spontaneous downstream signaling, in direct opposition to the action of agonists that promote the active state.^[39] Unlike neutral antagonists, which merely prevent agonist-induced activation without affecting basal activity, inverse agonists actively suppress this inherent receptor tone by favoring the inactive receptor form.^[40] The concept of inverse agonism emerged in the 1980s through studies on G protein-coupled receptors (GPCRs), where researchers identified basal activity in systems like opioid and adrenergic receptors, leading to the recognition of ligands that could inhibit this tone beyond simple blockade.^[41] Representative examples include prazosin, which acts as an inverse agonist at alpha-1 adrenergic receptors by suppressing constitutive activity in mutant models of the alpha-1a subtype, contributing to its effects beyond neutral antagonism.^[42] Similarly, second-generation antihistamines such as cetirizine function as inverse agonists at histamine H1 receptors, reducing basal signaling associated with allergic responses.^[43] Inverse agonists hold therapeutic importance in conditions involving overactive or constitutively active receptors, such as certain cancers where upregulated GPCR signaling promotes tumor growth, allowing these agents to inhibit proliferation by dampening basal activity.^[44]

Binding and Interaction Types

Orthosteric Modulators

Orthosteric modulators are pharmacological agents that bind directly to the orthosteric site of a receptor, defined as the primary binding pocket occupied by the endogenous agonist or ligand. This site is evolutionarily conserved across receptor subtypes and species, enabling these modulators to either mimic the natural ligand's effects or competitively displace it, thereby directly influencing receptor activation or inhibition. Unlike modulators acting at remote sites, orthosteric binding occurs at the active site, allowing for straightforward competition with physiological ligands.^[45]^[46] The mechanism of orthosteric modulators involves stabilizing specific receptor conformations through interactions within the orthosteric pocket, which typically comprises key amino acid residues that contact the endogenous ligand. This binding induces allosteric-like changes in the receptor's transmembrane domains or extracellular loops, propagating signals to alter downstream signaling pathways such as G-protein coupling or ion channel gating. Most small-molecule drugs in clinical use target orthosteric sites due to their druggability and accessibility, with examples including nicotine, which serves as an orthosteric agonist at nicotinic acetylcholine receptors (nAChRs) by activating neuronal signaling in the central nervous system, and caffeine, an orthosteric antagonist at adenosine receptors that blocks inhibitory effects to promote alertness. These modulators can manifest various intrinsic activities, from full agonism to antagonism, depending on their structural fit and efficacy at the site.^[2]^[47]^[48] Orthosteric sites offer advantages in drug development, including high binding potency and affinity due to their conserved architecture, which facilitates the design of potent inhibitors or activators with predictable pharmacokinetics. However, this conservation often results in reduced selectivity, increasing the risk of off-target binding to homologous receptors and potential side effects, as seen in broad-spectrum antagonists. Structural biology techniques, particularly X-ray crystallography, have been pivotal since the early 2000s in mapping these pockets; for instance, the first GPCR structure (bovine rhodopsin) in 2000 revealed a compact orthosteric pocket lined by transmembrane helices, enabling rational drug design for targets like beta-adrenergic and opioid receptors.^[49]^[50]

Allosteric Modulators

Allosteric modulators are ligands that bind to specific sites on a receptor, distinct from the orthosteric (primary agonist-binding) site, thereby altering the receptor's response to endogenous agonists without directly activating the receptor themselves.^[2] This binding modulates the affinity or efficacy of the agonist at the orthosteric site, enabling fine-tuned regulation of receptor function.^[51] Unlike orthosteric ligands, which compete directly with agonists for the active site, allosteric modulators exert their effects through remote conformational influences.^[2] Allosteric modulators are classified into two main types based on their effects: positive allosteric modulators (PAMs), which enhance the binding affinity or efficacy of the agonist, thereby potentiating receptor activation; and negative allosteric modulators (NAMs), which decrease agonist affinity or efficacy, attenuating receptor signaling.^[52] PAMs amplify physiological responses in a manner proportional to endogenous ligand levels, while NAMs suppress them, offering a "dimmer switch" control over receptor activity rather than binary on/off effects.^[2] Neither type exhibits intrinsic efficacy on their own, as they require the presence of an orthosteric agonist to manifest effects.^[51] The mechanism of allosteric modulation involves binding to an allosteric site, which induces a conformational change in the receptor protein that is transmitted to the orthosteric site, altering its shape or dynamics.^[53] This allosteric coupling can affect agonist binding kinetics, signal transduction pathways, or receptor desensitization without displacing the agonist.^[54] For instance, benzodiazepines act as PAMs at GABA_A receptors by binding to a distinct site on the receptor's extracellular domain, increasing the frequency of chloride channel opening in response to GABA, which hyperpolarizes neurons and reduces excitability.^[55] This mechanism underpins their use as anxiolytics for treating anxiety disorders, insomnia, and seizures.^[55] Similarly, cinacalcet functions as a PAM at the calcium-sensing receptor (CaSR), enhancing the receptor's sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion in patients with secondary hyperparathyroidism associated with chronic kidney disease.^[53]^[51] Allosteric modulators offer key advantages in pharmacology, including higher subtype selectivity due to the less conserved nature of allosteric sites compared to orthosteric ones, which can lead to fewer off-target effects and improved safety profiles.^[51] Their ability to preserve the tissue-specific signaling patterns of endogenous agonists further minimizes side effects.^[2] Since the 2010s, allosteric modulation has gained prominence in drug discovery, with increased focus on developing PAMs and NAMs for challenging targets like G-protein-coupled receptors, as evidenced by regulatory approvals like cinacalcet in 2004 and subsequent pipelines targeting CNS and metabolic disorders.^[2]^[51]

Competitive vs Non-competitive Binding

Competitive binding occurs when a receptor modulator and an agonist compete for the same orthosteric binding site on the receptor, leading to reversible and surmountable antagonism.^[56] In this scenario, increasing the concentration of the agonist can displace the modulator and restore the full receptor response, as the interaction follows the law of mass action, where the rate of binding is proportional to the concentrations of the reactants.^[57] This type of antagonism shifts the dose-response curve to the right without altering the maximum efficacy.^[22] In contrast, non-competitive binding involves the modulator attaching to a distinct site from the agonist or forming an irreversible bond, resulting in insurmountable antagonism that reduces the maximum response even at high agonist concentrations.^[56] Mechanistically, non-competitive modulators can alter receptor conformation, disrupt channel gating, or irreversibly modify signaling pathways, thereby decreasing the number of functional receptors available or impairing their activation.^[22] Allosteric modulators exemplify non-competitive binding by influencing the orthosteric site indirectly without direct competition.^[58] A classic example of competitive binding is atropine, which reversibly antagonizes muscarinic acetylcholine receptors by occupying the same site as acetylcholine, allowing higher agonist doses to overcome its effects.^[59] Conversely, phenoxybenzamine demonstrates non-competitive binding through covalent, irreversible attachment to alpha-adrenergic receptors, permanently inactivating them and preventing full agonist-induced responses.^[60] The potency of these modulators is often quantified using the IC50, the concentration required to inhibit 50% of the agonist response, while affinity is measured by the dissociation constant (Kd), indicating the equilibrium binding strength.^[61] In competitive scenarios, IC50 values shift with agonist concentration per the Cheng-Prusoff equation, whereas non-competitive IC50 remains constant, reflecting reduced efficacy.^[61]

Selective Receptor Modulators

Receptor Subtype Selectivity

Receptor subtype selectivity refers to the ability of a modulator to preferentially bind to and activate or inhibit one specific subtype within a family of related receptors, thereby minimizing interactions with other subtypes to reduce off-target effects. This property is quantified by the ratio of binding affinities or potencies (e.g., EC50 or IC50 values) between subtypes, where a higher ratio indicates greater selectivity. For instance, in G-protein-coupled receptor families like adrenergic receptors, subtype selectivity allows targeted modulation of physiological responses without broadly affecting the entire receptor class.^[62]^[63] The mechanism underlying subtype selectivity arises from subtle structural variations in the receptor binding pockets, such as differences in amino acid residues that influence ligand docking and conformational changes. These variations enable ligands to form more favorable interactions, like hydrogen bonds or hydrophobic contacts, with one subtype over another. Computational studies, including homology modeling, have revealed how these pocket differences dictate selectivity; for example, distinct residue orientations in beta-adrenergic subtypes allow ligands to stabilize specific active states. Mutagenesis experiments further confirm this by altering key residues to shift selectivity profiles, demonstrating that even single-point mutations can enhance or abolish subtype preference.^[64]^[65] Development of subtype-selective modulators has advanced through rational drug design since the 1990s, leveraging homology modeling to predict receptor structures when crystal structures were unavailable and site-directed mutagenesis to validate binding hypotheses. These approaches facilitated the optimization of lead compounds by iteratively refining ligand structures to exploit subtype-specific pockets, as seen in early efforts to differentiate beta-adrenergic antagonists. High-throughput screening combined with these tools accelerated the identification of selective candidates, transitioning from non-selective prototypes to clinically viable drugs.^[66]^[67]^[68] Prominent examples include metoprolol, a beta-1 adrenergic receptor-selective antagonist primarily targeting cardiac tissue, and salbutamol (albuterol), a beta-2 selective agonist used for bronchodilation in the lungs. Metoprolol exhibits approximately 100-fold selectivity for beta-1 over beta-2 receptors, allowing effective control of heart rate and blood pressure with minimal respiratory impact. Salbutamol, with approximately 20- to 30-fold beta-2 selectivity, relaxes airway smooth muscle while sparing cardiac beta-1 effects, making it suitable for asthma treatment.^[69]^[70]^[71] The primary benefit of subtype selectivity is the reduction of adverse effects by avoiding unintended modulation of non-target subtypes, enhancing therapeutic windows. For beta-1 selective blockers like metoprolol, this selectivity prevents beta-2-mediated bronchoconstriction, enabling safer use in patients with respiratory conditions compared to non-selective agents. Such precision has improved outcomes in cardiovascular and pulmonary therapies, with clinical data showing lower incidences of side effects like wheezing or fatigue.^[72]^[73]

Tissue or Organ Selectivity

Tissue or organ selectivity in receptor modulators refers to the ability of these compounds to preferentially influence receptor activity in specific tissues or organs, rather than exerting uniform effects across the body. This selectivity is primarily achieved through pharmacokinetic factors, such as differential drug delivery, metabolism, and absorption, as well as physiological variations like receptor density and the expression of co-regulatory proteins across tissues. For instance, lipid-soluble modulators can preferentially penetrate the blood-brain barrier to target central nervous system receptors, while prodrugs may be activated via tissue-specific enzymes, such as cytochrome P450 in the liver.^[5]^[74] Mechanisms contributing to this selectivity include variations in receptor subtype distribution and the recruitment of tissue-specific coactivators or corepressors, which alter the modulator's agonistic or antagonistic effects based on the local cellular environment. In selective estrogen receptor modulators (SERMs), for example, tamoxifen acts as an antagonist in breast tissue—reducing cancer recurrence by 40-50%—but as an agonist in bone, preserving density and preventing osteoporosis, due to differential co-regulator expression like SRC-1 in bone versus NCoR in breast cells. Similarly, selective androgen receptor modulators (SARMs), such as enobosarm, exhibit enhanced anabolic effects in muscle and bone compared to the prostate, leveraging higher androgen receptor density in skeletal muscle and avoidance of 5α-reduction, which limits prostate stimulation; preclinical data show high tissue selectivity (e.g., >100-fold in muscle versus prostate models).^[5]^[75]^[74] Clinically, this selectivity improves therapeutic efficacy while minimizing off-target adverse effects, particularly in hormone therapies for cancer and musculoskeletal disorders. Tamoxifen's breast-specific antagonism has made it a cornerstone for estrogen receptor-positive breast cancer treatment, lowering recurrence risk without broadly disrupting estrogenic benefits elsewhere, though it carries endometrial risks due to uterine agonism. SARMs like enobosarm have demonstrated gains in lean body mass (e.g., +1.3 kg over 12 weeks in cachexia patients) and anti-tumor activity in breast cancer (29-32% clinical benefit at 24 weeks), offering safer alternatives to traditional androgens by sparing prostate and cardiovascular tissues.^[5]^[74] Recent research advances, particularly post-2020, have extended tissue selectivity through gene therapy using synthetic and tissue-specific promoters to enable targeted receptor modulation. For example, muscle-specific promoters like SPc5-12 in AAV vectors have enhanced expression 6-8-fold over ubiquitous promoters in Duchenne muscular dystrophy trials, allowing precise delivery of receptor-modulating transgenes to skeletal muscle without systemic effects (NCT05693142; as of 2024, interim data showed sustained microdystrophin expression). Liver-targeted promoters such as HCB have shown 14-fold higher activity in hemophilia gene therapy, facilitating localized modulation of coagulation factor receptors (NCT04676048). These approaches complement receptor subtype selectivity by focusing on distributional targeting for safer, organ-restricted interventions.^[76]^[77]

References

[1]
The receptor concept: pharmacology's big idea - PMC
The receptor concept is to pharmacology as homeostasis is to physiology, or metabolism to biochemistry. They provide the basic framework, and are the 'Big Ideas ...
[2]
Allosteric Modulators: An Emerging Concept in Drug Discovery - PMC
Jan 8, 2015 · Allosteric modulators bind to secondary sites, altering the main binding site. They can be positive (PAMs) or negative (NAMs) modulators.
[3]
Allosteric Modulation of Class A GPCRs: Targets, Agents, and ...
GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery ...<|control11|><|separator|>
[4]
Selective Receptor Modulator - an overview | ScienceDirect Topics
Selective receptor modulators are defined as agents that selectively modulate the activity of specific androgenic or estrogenic receptors, ...
[5]
Selective estrogen receptor modulators: tissue specificity and ...
Aug 28, 2014 · Selective estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that function as ligands for ERs. However, unlike ...Serms: Mechanism Of Tissue... · Triphenylethylene Serms · Benzothiophene SermsMissing: definition | Show results with:definition
[6]
Emergent Concepts of Receptor Pharmacology - PubMed
In addition, the introduction of molecular dynamics, the appreciation of the allosteric nature of receptors, protein X-ray crystal structures, genetic ...
[7]
Receptor Modulator - an overview | ScienceDirect Topics
Receptor Modulator. In subject area: Chemistry. Receptor modulators are defined as compounds that influence the activity of specific receptors, which can ...
[8]
Physiology, Cellular Receptors - StatPearls - NCBI Bookshelf - NIH
Sep 19, 2024 · The 3 types of cell-surface receptors include G protein–coupled receptors (GPCRs), ion channel receptors, and enzyme-linked receptors. G ...
[9]
An overview of pharmacodynamic modelling, ligand-binding ...
Jul 9, 2016 · Affinity describes strength of drug binding with receptor (“fit the lock”). Efficacy describes ability of drug-bound receptor to produce a ...
[10]
The Chemical Basis of Pharmacology - PMC - PubMed Central - NIH
The distinction between the α and β adrenergic receptors was strengthened by the appearance of the first β-blockers, such as propanolol. ... receptor modulator; ...
[11]
Current strategies toward safer mu opioid receptor drugs for pain ...
MOR agonists that are currently prescribed for pain management include morphine, oxycodone and fentanyl. Although these MOR targeted opioids are the most potent ...<|control11|><|separator|>
[12]
Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical ...
The α-2 adrenergic receptor agonists have been used for decades to treat common medical conditions such as hypertension; attention-deficit/hyperactivity ...
[13]
Antiemetic Histamine H1 Receptor Blockers - StatPearls - NCBI - NIH
Mar 10, 2024 · First-generation antihistamines with antiemetic properties have several indications, predominantly for nausea and vomiting caused by motion sickness and ...
[14]
HMG-CoA Reductase Inhibitors - StatPearls - NCBI Bookshelf
HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary and secondary prevention of coronary heart disease.Continuing Education Activity · Indications · Mechanism of Action · Administration
[15]
Advances in G Protein-Coupled Receptor High-throughput Screening
Computational and experimental high-throughput screening (HTS) approaches of clinically relevant GPCRs are a first-line drug discovery effort in biomedical ...
[16]
Empirical Analysis of Drug Targets for Nervous System Disorders
Jan 18, 2024 · GPCR- and enzyme-targeting drugs are the two most common classes, each representing about 30% of FDA-approved drugs. Ion channel-targeting and ...
[17]
G Protein-Coupled Receptors as Targets for Approved Drugs - NIH
We estimate that ∼700 approved drugs target GPCRs, implying that approximately 35% of approved drugs target GPCRs.
[18]
https://pmc.ncbi.nlm.nih.gov/articles/PMC6165953/
[19]
Making Sense of Pharmacology: Inverse Agonism and Functional ...
Traditional receptor theory postulated that receptors in a population are quiescent unless activated by a ligand. Within this framework ligands could act as ...
[20]
Activation pathway of a G protein-coupled receptor uncovers ...
Aug 5, 2021 · Since agonist binding shifts the receptor conformational ensemble toward the active state, resulting in increased conformational dynamics and ...
[21]
Mu Receptors - StatPearls - NCBI Bookshelf - NIH
Jun 8, 2024 · The mu (μ) receptors are a class involved in neuromodulating different physiological functions. These receptors primarily affect nociception but also stress, ...Introduction · Clinical Significance · Enhancing Healthcare Team...
[22]
Epinephrine: Uses, Interactions, Mechanism of Action - DrugBank
Epinephrine acts on alpha and beta-adrenergic receptors. Epinephrine acts on alpha and beta receptors and is the strongest alpha receptor activator. Through its ...
[23]
basic_principles_of_pharm [TUSOM | Pharmwiki] - TMedWeb
Aug 18, 2019 · In contrast, full agonists produce a full or maximal response. In figure 4, Drug A is a full agonist, and Drugs B, C & D are partial agonists.
[24]
Beta2-Agonists - StatPearls - NCBI Bookshelf - NIH
Beta-2 adrenergic receptor agonists are a class of medications used in the frontline management and treatment of bronchial asthma and COPD.Continuing Education Activity · Introduction · Function · Issues of Concern
[25]
Partial Agonist - an overview | ScienceDirect Topics
A partial agonist is a drug that interacts with a receptor but produces less than the maximal effect.<|control11|><|separator|>
[26]
On the nature of partial agonism in the nicotinic receptor superfamily
Partial agonists are ligands which bind to receptors but produce only a small maximum response even at concentrations where all receptors are occupied.
[27]
Mechanism of gating and partial agonist action in the glycine receptor
Partial agonists produce distinct ECD and ECD-TMD conformational changes. To understand the conformational changes associated with transition from the closed- ...
[28]
Towards understanding the structural basis of partial agonism ... - NIH
Common conformational changes induced by partial agonists. We carried out comparative conformational analysis using PIA-GPCR on the simulations results of D3 ...
[29]
Partial Agonism - an overview | ScienceDirect Topics
Partial agonists induce conformational changes in FXR-LBD compared to full agonists (Fig. 3) [38]. These conformational changes may induce activation of FXR ...
[30]
Full agonists, partial agonists and inverse agonists
Sep 8, 2024 · A full agonist is a drug which is capable of producing a maximum response that the target system is capable of.
[31]
Buprenorphine - StatPearls - NCBI Bookshelf
Due to its partial opioid receptor agonist activity, buprenorphine is less likely to cause euphoria compared to full agonists such as methadone or morphine ...
[32]
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
Aripiprazole has a unique mechanism of action as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist.<|separator|>
[33]
Inverse agonism or neutral antagonism at G-protein coupled receptors
Agents that affect only ligand-dependent receptor activation, i.e. have no effect on constitutive receptor signalling, are termed neutral antagonists and turn ...
[34]
may a neutral antagonist shift an agonist concentration-response ...
It is generally accepted that the presence of a competitive antagonist shifts an agonist concentration-response curve to the right.
[35]
Neutral antagonist activity of naltrexone and 6β‐naltrexol in naïve ...
Mar 31, 2009 · Naltrexone, 6β-naltrexol and naloxone were indistinguishable to the μ-opioid receptor in the opioid-naïve or dependent state and acted as neutral antagonists.
[36]
Propranolol - StatPearls - NCBI Bookshelf - NIH
Propranolol is a competitive beta-adrenergic receptor antagonist devoid of agonist activity, making it the prototype for comparison to other beta-antagonists.
[37]
Design and models for estimating antagonist potency (pA2, Kd and ...
Schild (1957) derived the following log 10 DR−1 =− log 10 K d + log 10 ANAG where DR is the dose ratio and [ANAG] is the molar concentration of the antagonist.
[38]
The Relative Potency of Inverse Opioid Agonists and a Neutral ... - NIH
Studies strongly suggest that the commonly used opioid antagonists naloxone and naltrexone display negative efficacy and are therefore classified as inverse ...
[39]
Inverse Agonist - an overview | ScienceDirect Topics
Inverse agonist is defined as a ligand that binds to a receptor and inhibits or eliminates the basal or constitutive activity of that receptor, particularly in ...
[40]
Molecular mechanism of agonism and inverse agonism in ghrelin ...
Jan 13, 2022 · In pharmacology, inverse agonists bind to the orthosteric site ... The ghrelin peptide represents high activation potency as a full agonist ...
[41]
Inverse agonism: the classic concept of GPCRs revisited - J-Stage
In this review, we discuss inverse agonists, which are defined as GPCR ligands that shift the equilibrium toward the inactive state and thereby suppress the ...
[42]
Constitutive activation of G protein-coupled receptors and diseases
The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first described in 1980s. In 1991, the first naturally occurring ...
[43]
Inverse agonism and neutral antagonism at a constitutively active ...
Jan 29, 2009 · We have studied the antagonist action of prazosin and KMD-3213 in a constitutively active mutant of the human alpha-1a adrenoceptor in which ...
[44]
Pharmacology of Antihistamines | World Allergy Organization Journal
Mar 15, 2011 · This article reviews the molecular biology of the interaction of histamine with its H 1 -receptor and describes the concept that H 1 -antihistamines are not ...
[45]
Inverse Agonist - an overview | ScienceDirect Topics
An inverse agonist, also known as a negative antagonist, is a type of ligand that exhibits negative efficacy. It is suggested that the nomenclature of inverse ...
[46]
Inverse agonism and its therapeutic significance - PubMed Central
Inverse agonists bind with the constitutively active receptors, stabilize them, and thus reduce the activity (negative intrinsic activity). Receptors of many ...
[47]
Drugs for Allosteric Sites on Receptors - PMC - PubMed Central
Each receptor/protein possesses a distinctive binding site for its respective endogenous ligand(s) that is defined as the orthosteric binding site, and both ...
[48]
International Union of Basic and Clinical Pharmacology. XC ...
In this regard, “orthosteric” ligands are defined as those that display mutually exclusive binding with the endogenous agonist of the receptor by virtue of ...
[49]
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine ...
This led to the introduction of a series of nAChR agonists and partial agonists including ABT-418 and ABT-089. ABT-418 is a full nAChR agonist with apparent ...Missing: caffeine | Show results with:caffeine
[50]
Pathways and Mechanism of Caffeine Binding to Human Adenosine ...
Apr 26, 2021 · Caffeine is a common antagonist to the four subtypes of adenosine G-protein-coupled receptors (GPCRs), which are critical drug targets for ...
[51]
GPCR Allosteric Modulators: Mechanistic Advantages and ...
Dec 28, 2019 · GPCR-targeted orthosteric small molecules may exhibit disadvantages such as difficulty binding diffuse orthosteric sites with high affinity ...
[52]
G protein-coupled receptors (GPCRs): advances in structures ...
Apr 10, 2024 · G protein-coupled receptors (GPCRs) are the largest superfamily of cell surface membrane receptors and are encoded by approximately 1000 genes, ...
[53]
https://www.nature.com/articles/srep46355
[54]
Allosteric Modulators of Sigma-1 Receptor: A Review - Frontiers
Mar 18, 2019 · Allosteric modulators can be positive or negative effectors (PAMs or NAMs, respectively). PAMs increase the activity of the ligand, while NAMs ...
[55]
Investigating the molecular mechanism of positive and negative ...
Apr 18, 2017 · Cinacalcet is a positive allosteric modulator (PAM) targeting CaSR and the very first GPCR allosteric modulator to get regulatory approval. It ...
[56]
Keynote review: Allosterism in membrane receptors - PubMed Central
The allosteric site on the GABAA receptor is the target for the most widely prescribed sleep medicines, the benzodiazepines. Cinacalcet, an allosteric enhancer ...
[57]
GABA Receptor Positive Allosteric Modulators - StatPearls - NCBI
Feb 28, 2024 · GABA receptor-positive allosteric modulators, encompassing benzodiazepines and barbiturates, are pivotal in addressing diverse medical conditions.
[58]
8. Two Main Classes of Receptor Ligands in Pharmacology
Drugs that do not interact with the agonist receptor but rather reduce the concentration of an agonist by forming a chemical complex; also known as chelating ...Missing: definition | Show results with:definition
[59]
6. Characteristics of Drug-Receptor Interactions
Follow Mass-Action Law: rate of reaction is DIRECTLY proportional to the concentration of the reactants, however, there is a limit.
[60]
10. Competitive Antagonist vs. Negative Allosteric Modulator
A competitive antagonist directly and physically blocks access of the agonist to the receptor, whereas a negative allosteric modulator indirectly changes ...
[61]
Atropine - StatPearls - NCBI Bookshelf - NIH
Jul 6, 2025 · Atropine is an anticholinergic agent that functions as a competitive, reversible antagonist of muscarinic receptors.
[62]
Phenoxybenzamine - StatPearls - NCBI Bookshelf - NIH
Phenoxybenzamine is a nonselective, irreversible antagonist of the alpha-adrenergic receptors.[8] Alpha-adrenergic receptors subdivide into alpha-1 and ...Continuing Education Activity · Mechanism of Action · Contraindications · Monitoring
[63]
[PDF] Analyzing Binding Data - University of Michigan Library
Therefore, increasing the concentration of radioligand will increase the IC50 without changing the Ki. 3. The affinity of the radioligand for the receptor (Kd).
[64]
Receptor selectivity | Pharmacology Education Project
Agonist selectivity is determined by the ratio of EC50 of the dose–response curve at the two different receptor subtypes.
[65]
Drug–Receptor Interactions - Clinical Pharmacology - Merck Manuals
A ligand may activate or inactivate a receptor; activation may increase or decrease a particular cell function. Each ligand may interact with multiple receptor ...<|separator|>
[66]
Distinct activation mechanisms regulate subtype selectivity ... - Nature
May 5, 2023 · We hypothesize that the subtype selectivity of designed selective ligands can be explained by the ligand binding to the conformationally distinct states ...
[67]
Molecular Basis for Binding and Subtype Selectivity of 1,4 ...
Ligand-directed homology modeling was utilized to generate predictive receptor models in which the geometry of the binding pockets and distinct residue ...
[68]
Rational Approaches to Improving Selectivity in Drug Design - PMC
... targeting drugs to specific cells offers a direct route to achieving selectivity. In addition to capitalizing upon the effect of cell trafficking on drug ...
[69]
Homology Modeling a Fast Tool for Drug Discovery - NIH
Homology modeling is a powerful tool to suggest modeling of ligand-receptor interactions, enzyme-substrate interactions, mutagenesis experiments, SAR data, ...
[70]
Structural interpretation of P2X receptor mutagenesis studies on ...
Mar 4, 2010 · Mutagenesis based studies have been used to develop an understanding of the molecular basis of their pharmacology with the aim of developing ...
[71]
The selectivity of β-adrenoceptor antagonists at the human β1, β2 ...
This study suggests that many ligands previously considered to have β1-selectivity, for example, metoprolol and atenolol (Lewis & Lofthouse, 1993), have poor β ...
[72]
Beta2 Receptor Agonists and Antagonists - StatPearls - NCBI - NIH
Some FDA-approved short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm ...
[73]
Albuterol: Uses, Interactions, Mechanism of Action | DrugBank Online
Albuterol is a beta-2 adrenergic receptor agonist used to treat asthma, bronchitis, COPD, as well as prevent exercise induced bronchospasms.
[74]
Selective Beta-1 Blockers - StatPearls - NCBI Bookshelf
Some medications that may result in adverse effects when paired with beta-1 blockers ... lowering or anti-arrhythmic medications. Adverse effects also ...
[75]
Better beta-blockers | Nature Reviews Drug Discovery
... drug was found to be selective for the β3-adrenoceptor. Some drugs ... drugs with greater selectivity and less side-effects for a range of indications.
[76]
Selective androgen receptor modulators: a critical appraisal - Frontiers
Sep 25, 2025 · Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of ...
[77]
Coregulator Function: A Key to Understanding Tissue Specificity of ...
Selective receptor modulators (SRMs) are receptor ligands that exhibit agonistic or antagonistic biocharacter in a cell- and tissue context-dependent manner.A. Selective Er Modulators... · B. Effect Of Ligand On... · Iv. Molecular Basis Of...
[78]
Synthetic Promoters in Gene Therapy: Design Approaches, Features ...
Tissue-specific promoters provide targeted expression in specific tissues or cells and are often associated with low levels of activity, whereas ubiquitous ...